Celebrating World Antimicrobial Awareness week!
It’s World Antimicrobial Awareness week!
Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites resist the effects of medications, making common infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.
Randox want to take part in the global campaign that is celebrated annually to improve awareness and understanding of Antimicrobial. We have interviewed one of our Molecular specialists, Dr Dwaine Vance on how our revolutionary Randox products aid in the fight against AMR.
What threat does AMR present to the health care environment?
In a worse-case scenario the increasingly worrying levels of AMR globally will have a significant negative effect on healthcare. Without effective antimicrobials to treat a wide arrange of infectious diseases, people will be more likely to get ill, be unresponsive to medications, which in turn will result in longer hospital stays, increased economic burden, lower levels of quality of life and ultimately poorer prognosis including elevated levels of morbidity and mortality.
How does Randox help in the fight against AMR?
Randox have developed and continue to develop infectious disease tests to detect a wide-range infectious disease. Randox have also included resistance gene markers within these molecular-based PCR tests to determine if an infection is sensitive or resistance to certain antimicrobials.
In addition to diagnostic tests, Randox also supply quality control materials such as third-party molecular controls and external quality assessment schemes that are used in molecular microbiology laboratories to ensure their PCR tests are working accurately and robustly. This means that labs can provide the correct information to clinicians that is vitally important to determine what antibiotic therapy is prescribed to the patient.
Can you tell us about any exciting developments in Randox?
Randox are continuously investing and reinvesting in our Molecular Research and Development departments. We have recently released a molecular point of care test that can discriminate between MRSA and MSSA. This means that sufficient isolation and correct primary treatment can be provided to the patient in a timelier fashion. We are in the process of releasing a UTI test that can detect over 20 UTI-related bacterial infections. In addition to these pathogens, this test also determines if the pathogens detected are resistant to commonly used antibiotics such as Trimethoprim or Vancomycin.
Furthermore, Randox are releasing an immunoassay-based point of care machine called the VerasSTAT, which includes tests for CRP and MxA biomarkers. These biomarkers are released into the bloodstream during infection as part of the body’s immune response. CRP and MxA can assist the clinician in determining if an infection is of bacterial or viral origin.
What measures do you think we can take to prevent the spread of AMR?
Improved personal hygiene and sanitation will reduce transmission of infectious diseases within the global population. The development of more innovative and more easily accessible antibiotics, as well as improved antibiotic stewardship within clinical settings will also help slow down the alarming rates of AMR globally. Most importantly, the creation of new syndromic style testing panels, like the tests currently provided by Randox will undoubtedly improve the clinical outcome for patients who are have an infectious disease.
We are urging the public to help raise awareness of antimicrobial resistance. Randox is committed to the ongoing development of products and services as well as our research into numerous disease areas to improve health worldwide.
This appointment is of strategic importance in Randox’s plans to increase its market presence in the United States. As part of this Randox is committed to increasing its on the ground leadership and customer support network, with a view to significantly expanding its US market share.
Schaefering brings a wealth of experience to Randox from a career spanning more than 20 years in the industry. He joins Randox from Bio-Rad where he was National Account Manager handling the negotiation and contract management for several GPOs and key accounts including Quest Diagnostics, MedAssets and Premier.
Moving to Randox, Schaefering said:
In today’s healthcare climate, labs are increasing looking for opportunities: opportunities to increase productivity; to be more efficient; to realize labor savings, but without sacrificing on quality. Randox brings opportunity and quality that has largely been missing in the US until now. With QC solutions that are increasingly regarded as the highest quality and most accurate available globally, Randox stands apart from the competition.
Randox Chief Customer Officer, David Brown said:
“Offering first-class customer support is one of the fundamental tenets on which Randox operates. As we grow our customer base in the US we are committed to also growing our customer support network. John Schaefering’s appointment is a key step to ensure our US customers have access to on the ground assistance as and when they need it.”
Randox has had the US market in its sights since 2010, when it opened its 33,000ft² US Headquarters in West Virginia following a multimillion dollar investment. The company’s determination to grow its US market share was reasserted earlier this year when it announced plans to expand its West Virginia HQ into a key manufacturing facility, significantly expanding the company’s capabilities Stateside.
Randox recently announced that it’s won a major supplier agreement with leading healthcare supply chain company Novation, meaning its third party quality control products will now be readily available to hospital organizations throughout the US.